Dr. Jason Zhu to Deliver Keynote at 2026 J.P. Morgan Healthcare Conference in San Francisco
The 44th J.P. Morgan Healthcare Conference is set to be held from January 12 to 15, 2026, in San Francisco, USA. This prestigious event is attended by industry leaders, promising emerging companies, and global investors, making it one of the largest and most influential healthcare conferences in the world. Dr. Jason Zhu, the CEO and Executive Director of Henlius, a global biopharmaceutical company, has been invited to deliver a keynote speech on January 15, 2026, during the conference.
Dr. Zhu will present Henlius's core competencies developed through its internationalization process. He will also discuss the latest advancements in the company's innovative pipeline and next-generation technology platforms. These include Antibody-Drug Conjugates (ADCs) and multispecific T-cell engagers (TCEs). Under Dr. Zhu's leadership, Henlius has transitioned from a nascent biotech company to a fully-scaled global biopharmaceutical firm with a significant international presence, emphasizing the need for high-quality, affordable biological drugs in oncology, autoimmune diseases, and eye disorders.
At the conference, Dr. Zhu is expected to delve into Henlius's strategic alignment for the next five years, showcasing how the company has integrated research and development, manufacturing, regulatory approvals, and marketing. By establishing clinical development, operational, and regulatory teams in key markets like the United States and Japan, Henlius has accelerated local development and market access, ensuring that it can conduct clinical trials independently and interact directly with global regulatory authorities.
The company prides itself on its GMP-certified commercial manufacturing facilities located in China, the EU, and the USA, establishing a global supply chain that extends across six continents. This robust infrastructure allows Henlius to continuously build its global market presence while forming long-term strategic partnerships with leading multinational pharmaceutical companies, creating a sustainable and scalable global development model.
Moreover, Henlius is committed to addressing the unmet needs of patients worldwide. By closely collaborating with global capital markets and industry partners, the company aims to strengthen its global innovation and operational capabilities further, striving to build a patient-centered biopharmaceutical model that delivers high-quality and affordable treatments to patients globally.
Since its establishment in 2010, Henlius has developed an integrated biopharmaceutical platform characterized by efficiency and innovation throughout the complete product lifecycle, including research, manufacturing, and marketing. Today, the company has ten products approved for marketing in several countries and regions, with five additional marketing applications accepted for review in China and the EU.
The company maintains a proactive approach to diversifying its product pipeline, which now encompasses approximately 50 molecules. Henlius has advanced research in immuno-oncological combination therapies centered around its proprietary HANSIZHUANG (Anti-PD-1 mAb) as a foundational element. Products already introduced by the company include HANSIZHUANG (Serplulimab, marketed as Hetronifly® in Europe), the world’s first anti-PD-1 mAb for the first-line treatment of small cell lung cancer (SCLC), among others, showcasing a diverse portfolio that addresses significant medical needs.
Henlius’s progress is evident as it continues to roll out clinical studies for 19 products while expanding its presence in key and emerging markets. The company’s unwavering dedication to delivering innovative biopharmaceutical solutions reflects its vision: to offer high-quality, affordable, and innovative biological medicines to patients around the world.
For further information about Henlius, please visit Henlius Official Website and connect with us on LinkedIn.
Dr. Zhu will present Henlius's core competencies developed through its internationalization process. He will also discuss the latest advancements in the company's innovative pipeline and next-generation technology platforms. These include Antibody-Drug Conjugates (ADCs) and multispecific T-cell engagers (TCEs). Under Dr. Zhu's leadership, Henlius has transitioned from a nascent biotech company to a fully-scaled global biopharmaceutical firm with a significant international presence, emphasizing the need for high-quality, affordable biological drugs in oncology, autoimmune diseases, and eye disorders.
At the conference, Dr. Zhu is expected to delve into Henlius's strategic alignment for the next five years, showcasing how the company has integrated research and development, manufacturing, regulatory approvals, and marketing. By establishing clinical development, operational, and regulatory teams in key markets like the United States and Japan, Henlius has accelerated local development and market access, ensuring that it can conduct clinical trials independently and interact directly with global regulatory authorities.
The company prides itself on its GMP-certified commercial manufacturing facilities located in China, the EU, and the USA, establishing a global supply chain that extends across six continents. This robust infrastructure allows Henlius to continuously build its global market presence while forming long-term strategic partnerships with leading multinational pharmaceutical companies, creating a sustainable and scalable global development model.
Moreover, Henlius is committed to addressing the unmet needs of patients worldwide. By closely collaborating with global capital markets and industry partners, the company aims to strengthen its global innovation and operational capabilities further, striving to build a patient-centered biopharmaceutical model that delivers high-quality and affordable treatments to patients globally.
Since its establishment in 2010, Henlius has developed an integrated biopharmaceutical platform characterized by efficiency and innovation throughout the complete product lifecycle, including research, manufacturing, and marketing. Today, the company has ten products approved for marketing in several countries and regions, with five additional marketing applications accepted for review in China and the EU.
The company maintains a proactive approach to diversifying its product pipeline, which now encompasses approximately 50 molecules. Henlius has advanced research in immuno-oncological combination therapies centered around its proprietary HANSIZHUANG (Anti-PD-1 mAb) as a foundational element. Products already introduced by the company include HANSIZHUANG (Serplulimab, marketed as Hetronifly® in Europe), the world’s first anti-PD-1 mAb for the first-line treatment of small cell lung cancer (SCLC), among others, showcasing a diverse portfolio that addresses significant medical needs.
Henlius’s progress is evident as it continues to roll out clinical studies for 19 products while expanding its presence in key and emerging markets. The company’s unwavering dedication to delivering innovative biopharmaceutical solutions reflects its vision: to offer high-quality, affordable, and innovative biological medicines to patients around the world.
For further information about Henlius, please visit Henlius Official Website and connect with us on LinkedIn.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.